JP2018533570A - ペプチド - Google Patents

ペプチド Download PDF

Info

Publication number
JP2018533570A
JP2018533570A JP2018520389A JP2018520389A JP2018533570A JP 2018533570 A JP2018533570 A JP 2018533570A JP 2018520389 A JP2018520389 A JP 2018520389A JP 2018520389 A JP2018520389 A JP 2018520389A JP 2018533570 A JP2018533570 A JP 2018533570A
Authority
JP
Japan
Prior art keywords
peptide
amino acid
cells
amino acids
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018520389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533570A5 (enExample
Inventor
リチャード モーガン
リチャード モーガン
Original Assignee
エイチオーエックス セラピューティクス リミテッド
エイチオーエックス セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイチオーエックス セラピューティクス リミテッド, エイチオーエックス セラピューティクス リミテッド filed Critical エイチオーエックス セラピューティクス リミテッド
Publication of JP2018533570A publication Critical patent/JP2018533570A/ja
Publication of JP2018533570A5 publication Critical patent/JP2018533570A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
JP2018520389A 2015-10-21 2016-10-20 ペプチド Pending JP2018533570A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1518700.8 2015-10-21
GB1518700.8A GB2543550A (en) 2015-10-21 2015-10-21 Peptides
PCT/GB2016/053282 WO2017068353A1 (en) 2015-10-21 2016-10-20 Peptides

Publications (2)

Publication Number Publication Date
JP2018533570A true JP2018533570A (ja) 2018-11-15
JP2018533570A5 JP2018533570A5 (enExample) 2020-07-30

Family

ID=55131441

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018520389A Pending JP2018533570A (ja) 2015-10-21 2016-10-20 ペプチド

Country Status (13)

Country Link
US (1) US10494412B2 (enExample)
EP (2) EP3364992B1 (enExample)
JP (1) JP2018533570A (enExample)
KR (1) KR20180080217A (enExample)
CN (1) CN108430491A (enExample)
AU (1) AU2016341494A1 (enExample)
BR (1) BR112018008136A2 (enExample)
CA (1) CA3002739A1 (enExample)
EA (1) EA201890900A1 (enExample)
ES (1) ES2775740T3 (enExample)
GB (1) GB2543550A (enExample)
MX (1) MX2018004930A (enExample)
WO (1) WO2017068353A1 (enExample)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019568A1 (en) * 1994-01-14 1995-07-20 Matthias Rath Hydrophilic signal oligopeptides and methods of therapeutic use
JP2006520745A (ja) * 2002-12-13 2006-09-14 セント ジョージズ エンタープライジズ リミテッド Ｐｂｘ依存性遺伝子調節を阻害するペプチド
JP2009500314A (ja) * 2005-06-29 2009-01-08 セント ジョージス エンタープライシス リミテッド 遺伝子調節
US20090030178A1 (en) * 2006-08-02 2009-01-29 Phoenix Pharmaceuticals, Inc. Cell permeable bioactive peptide conjugates

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5608082A (en) 1994-07-28 1997-03-04 Agouron Pharmaceuticals, Inc. Compounds useful as antiproliferative agents and GARFT inhibitors
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6573293B2 (en) 2000-02-15 2003-06-03 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
AR032028A1 (es) 2001-01-05 2003-10-22 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20050148627A1 (en) 2003-03-31 2005-07-07 Jeffery Carter Benzopyran compounds for use in the treatment and prevention of inflammation related conditions
US7259266B2 (en) 2003-03-31 2007-08-21 Pharmacia Corporation Benzopyran compounds useful for treating inflammatory conditions
ES2633453T3 (es) * 2008-01-24 2017-09-21 Esperance Pharmaceuticals Constructos de fusión de dominios líticos y métodos de preparación y utilización de los mismos
JP6943759B2 (ja) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 シフト装置

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019568A1 (en) * 1994-01-14 1995-07-20 Matthias Rath Hydrophilic signal oligopeptides and methods of therapeutic use
JP2006520745A (ja) * 2002-12-13 2006-09-14 セント ジョージズ エンタープライジズ リミテッド Ｐｂｘ依存性遺伝子調節を阻害するペプチド
JP2009500314A (ja) * 2005-06-29 2009-01-08 セント ジョージス エンタープライシス リミテッド 遺伝子調節
US20090030178A1 (en) * 2006-08-02 2009-01-29 Phoenix Pharmaceuticals, Inc. Cell permeable bioactive peptide conjugates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BESSALLE R, JOURNAL OF MEDICINAL CHEMISTRY, vol. VOL:36, NR:9, JPN5018007252, 1993, US, pages 1203 - 1209, ISSN: 0004384745 *

Also Published As

Publication number Publication date
CN108430491A (zh) 2018-08-21
AU2016341494A1 (en) 2018-05-24
EA201890900A1 (ru) 2018-10-31
ES2775740T3 (es) 2020-07-28
GB2543550A (en) 2017-04-26
WO2017068353A1 (en) 2017-04-27
MX2018004930A (es) 2018-11-09
EP3364992B1 (en) 2019-12-04
US10494412B2 (en) 2019-12-03
EP3364992A1 (en) 2018-08-29
CA3002739A1 (en) 2017-04-27
BR112018008136A2 (pt) 2018-11-06
GB201518700D0 (en) 2015-12-02
ES2775740T8 (es) 2020-08-06
US20180282384A1 (en) 2018-10-04
EP3610883A1 (en) 2020-02-19
KR20180080217A (ko) 2018-07-11

Similar Documents

Publication Publication Date Title
RU2361592C2 (ru) Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы
Lu et al. Targeting p53 for enhanced radio-and chemo-sensitivity
AU2016370846B2 (en) Combinations for the treatment of cancer
US20050272755A1 (en) Method for treating abnormal cell growth
WO2010033771A2 (en) Modulators of hsp70/dnak function and methods of use thereof
WO2008053319A1 (en) Amide resorcinol compounds
JP2022520997A (ja) イミプリドンを使用する方法
US20090312280A1 (en) Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
Impicciatore et al. Nutlins and ionizing radiation in cancer therapy
US20220098196A1 (en) Trapping-free parp inhibitors
Stokłosa et al. Prospects for p53-based cancer therapy.
CN104039797A (zh) 作为细胞凋亡诱导剂的杂环分子
EP3364992B1 (en) Peptides
US20190256502A1 (en) Organic compounds
WO2012117224A1 (en) Dipyridinium derivatives
CN120365366A (zh) 一组广谱杀死肿瘤细胞并引起肿瘤细胞免疫原性死亡的多肽及其制备方法、给药系统和应用
CN120349384A (zh) 一种能引起肿瘤细胞免疫原性死亡的多肽及其制备方法、给药系统和应用
CN120349383A (zh) 能引起肿瘤细胞免疫原性死亡，广谱杀死肿瘤细胞的多肽及其制备方法、给药系统和应用
CN120365375A (zh) 有效杀死肿瘤细胞并引起肿瘤细胞免疫原性死亡的多肽及其制备方法、给药系统和应用
CN101384264B (zh) 含有聚（adp-核糖）聚合酶抑制剂的治疗组合物
AU2011253816A1 (en) Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor
HK1127956A (en) Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210614